ReviewKorean journal of pediatrics2014
Efficacy and safety of growth hormone treatment for children born small for gestational age.
Review in Korean journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Growth hormone effect on body composition of children born small for gestational age: a systematic review.Jornal de pediatriaPooled it
- Effect of treatment with growth hormone on body composition and metabolic profile of short children born small for gestational age.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024Trial
- Early postnatal growth predictors of catch-up growth in term small-for-gestational-age infants: a nationwide propensity-score-matched study.Frontiers in endocrinology · 2026Article
- Article
- Article
- Determinants of adverse event occurrence in children with short stature born small for gestational age treated with growth hormone.Frontiers in endocrinology · 2025Observational
- Improving growth in preterm infants through nutrition: a practical overview.Frontiers in nutrition · 2024Review
- The Exon 3-Deleted Growth Hormone Receptor (d3GHR) Polymorphism-A Favorable Backdoor Mechanism for the GHR Function.International journal of molecular sciences · 2023Review
- Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study.Clinical endocrinology · 2022Observational
- Long-term effectiveness of growth hormone therapy in children born small for gestational age: An analysis of LG growth study data.PloS one · 2022Article
- Factors influencing growth hormone therapy effect during the prepubertal period in small for gestational age children without catch-up growth.Annals of pediatric endocrinology & metabolism · 2021Article
- Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.Acta bio-medica : Atenei Parmensis · 2020Article
- First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormone.Journal of endocrinological investigation · 2019Article
- A randomized controlled trial to compare the effects of liquid versus powdered recombinant human growth hormone in treating patients with severe burns.Biomedical reports · 2016Article
- Drug-Induced Hyperglycaemia and Diabetes.Drug safety · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. GH treatment at a dose of 35-70 µg/kg/day should be considered for those with very marked growth retardation, as these patients require rapid catch-up growth. Factors associated with response to GH treatment during the initial 2-3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. Adverse events due to GH treatment are no more common in the SGA population than in other conditions treated with GH. Early surveillance in growth clinics is strongly recommended for children born SGA who have not caught up. Although high dose of up to 0.067 mg/kg/day are relatively safe for short children with growth failure, clinicians need to remain aware of long-term mortality and morbidity after GH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.